bimekizumab · Bimzelx
Monoclonal antibody
Also known as UCB4940
Evidence outlook
Approved: Psoriasis (label: moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or...), Psoriatic Arthritis, Hidradenitis Suppurativa
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (5)
- Non-Radiographic Axial Spondyloarthritis BIMZELX is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation.
- Ankylosing Spondylitis BIMZELX is indicated for the treatment of adults with active ankylosing spondylitis.
- Bimzelx (bimekizumab injection) is indicated for: • Psoriasis (PsO) The treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. • Psoriatic arthritis (PsA) The treatment of adult patients with active psoriatic arthritis. Bimzelx can be used alone or in combination with a conventional non-biologic disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate). • Axial Spondyloarthritis (axSpA) Ankylosing Spondylitis (AS, radiographic spondyloarthritis) The treatment of adult patients with active ankylosing spondylitis...
- Plaque psoriasis, generalized pustular psoriasis and psoriatic erythroderma in patients not sufficiently responding to existing treatments (UCB release dated 2022-01-24)
- Moderate-to-severe plaque psoriasis in adults (first indication); current label includes PsA, axSpA and hidradenitis suppurativa
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
BE VIVID NCT03370133 · Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis This was a randomized, quadruple-blind, placebo- and active-controlled phase 3 trial involving 567 participants. Both prespecified clinical skin endpoints at week 16—PASI90 and Investigator’s Global Assessment response—were significantly better with bimekizumab than with placebo and ustekinumab (all p<0.001). Registry: NCT03370133 | 3 | Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16; Percentage of Participants With an Investigator's Global Assessment (IGA) (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) Response at Week 16 2019-01-08 | Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 (Week 16): Bimekizumab 320 mg Q4W (RS) 85% vs Placebo (RS) 4.8% vs Ustekinumab (RS) 49.7% | Reliable signal | link ↗ |
View 4 more trials
NCT06624228 NCT06624228 · Psoriatic Arthritis The study randomized 553 participants to bimekizumab or the active comparator risankizumab and used quadruple blinding. Its primary endpoint is the clinical ACR50 response at Week 16, but the comparison and outcome are not yet reported, so the evidence cannot be graded as showing a confirmed benefit. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT06624228 | 3 | American College of Rheumatology 50 (ACR50) at Week 16 2026-02-06 | ACR50 at Week 16 (BE BOLD): 49.1% bimekizumab vs 38.4% risankizumab; bimekizumab statistically significantly superior. | Partial signal | link ↗ |
BE READY NCT03410992 · Psoriatic Arthritis The study was randomized, quadruple-blind, placebo-controlled, and enrolled 435 participants; both prespecified Week 16 clinical psoriasis endpoints were met, with p<0.001 for each comparison. However, no power calculation or planned enrollment is reported in the provided record, so the evidence is graded moderate rather than strong. Registry: NCT03410992 | 3 | Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16; Percentage of Participants With an Investigator's Global Assessment (IGA) Response at Week 16 2018-12-28 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
BE OPTIMAL NCT03895203 · Psoriatic Arthritis Patients were randomized and the trial was blinded for participants, investigators and outcome assessors, with a placebo control and 852 patients enrolled against a planned 840 supported by a reported power calculation. The primary endpoint, ACR50 response at week 16, is a validated clinical measure, and bimekizumab beat placebo with a statistically significant result. Registry: NCT03895203 | 3 | Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Week 16 2021-08-17 | ACR50 at week 16: bimekizumab 160 mg Q4W 43.9% (n=431) vs placebo 10.0% (n=281), odds ratio 7.08 (95% CI 4.58 to 10.94), p<0.001; adalimumab reference arm 45.7% (n=140, not tested) (CT.gov posted results). | Reliable signal | link ↗ |
BE COMPLETE NCT03896581 · Psoriatic Arthritis Patients were randomized 2:1 and the trial was blinded for participants, investigators and outcome assessors, with a placebo control and 400 patients enrolled against a planned 390 supported by a reported power calculation. The primary endpoint, ACR50 response at week 16, is a validated clinical measure, and bimekizumab beat placebo with a statistically significant result. Registry: NCT03896581 | 3 | Percentage of Participants With American College of Rheumatology 50 (ACR50) Response (From Baseline to Week 16) 2021-12-08 | ACR50 at week 16: bimekizumab 160 mg 43.4% (n=267) vs placebo 6.8% (n=133), odds ratio 11.14 (95% CI 5.40 to 22.97), p<0.001 (CT.gov posted results). | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (25)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (14)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Appears in other studies (2)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2 (2)
What this study did
What this study did
Competitive landscape
Other IL-17A/F drugs
Lecankitug, sonelokimab, ORKA-002. Compare all 4 IL-17A/F drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Hidradenitis Suppurativa: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Bimekizumab (Bimzelx): this drug | Approved | Monoclonal antibody | IL-17A/F | Partial signal | NCT04242498: HiSCR50 at week 16: bimekizumab dosing regimen 1 53.8% (n=144) and regimen 2 52.0% (n=291) vs placebo 32.2% (n=74); odds ratios 2.42 (95% CI 1.22 to 4.80), p=0.004, and 2.29 (95% CI 1.22 to 4.29), p=0.003 (CT.gov posted results). NCT04242446: Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16 (Week 16): Placebo 28.7 percentage of participants (95% CI 18.1 to 39.3) | BKZ Dosing Regimen 1 45.3 percentage of participants (95% CI 36.8 to 53.8) | BKZ Dosing Regimen 2 47.8 percentage of participants (95% CI 41.8 to 53.7) | |
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aacf (Idacio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aaty (Yuflyma) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adaz (Hyrimoz) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Afzb (Abrilada) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aqvh (Yusimry) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Atto (Amjevita) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Bwwd (Hadlima) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Fkjp (Hulio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Ryvk (Simlandi) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Secukinumab (Cosentyx) | Approved | Monoclonal antibody | IL-17 | Partial signal | NCT03713632: Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50) (16 weeks): AIN457 Q2W 42.3 Percentage of Participants | AIN457 Q4W 46.1 Percentage of Participants | Placebo 31.2 Percentage of Participants NCT03713619: Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50) (16 weeks): Secukinumab 1 - Q2W 45 Percentage of participants | Secukinumab 2 - Q4W 41.8 Percentage of participants | Placebo 33.7 Percentage of participants | |
| Lutikizumab | Phase 3 | Multispecific antibody | IL-1α/IL-1β (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Remibrutinib | Phase 3 | Small molecule | Bruton's tyrosine kinase (BTK) | not yet graded | No reviewed efficacy summary in this indication | |
| Ruxolitinib (Opzelura) | Phase 3 | Small molecule | JAK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| Sonelokimab | Phase 3 | Antibody-derived scaffold | IL-17A/F | not yet graded | No reviewed efficacy summary in this indication | |
| Upadacitinib (Rinvoq) | Phase 3 | Small molecule | JAK, JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| BFB759 | Phase 2/3 | Monoclonal antibody | IL-1RAP | not yet graded | No reviewed efficacy summary in this indication | |
| Spesolimab (Spevigo) | Phase 2/3 | Monoclonal antibody | IL-36 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Abdakibart | Phase 2 | Monoclonal antibody | IL-1 beta | not yet graded | No reviewed efficacy summary in this indication | |
| Duvakitug | Phase 2 | Monoclonal antibody | TL1A | not yet graded | No reviewed efficacy summary in this indication | |
| Eltrekibart | Phase 2 | Monoclonal antibody | CXCR1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| Olatorepatide | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| ORKA-002 | Phase 2 | Monoclonal antibody | IL-17A/F | not yet graded | No reviewed efficacy summary in this indication | |
| SAR442970 | Phase 2 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| SAR445399 | Phase 2 | Monoclonal antibody | IL-1R3 (IL1RAP) | not yet graded | No reviewed efficacy summary in this indication | |
| SPY072 | Phase 2 | Monoclonal antibody | TL1A | not yet graded | No reviewed efficacy summary in this indication | |
| Tulisokibart | Phase 2 | Monoclonal antibody | TL1A | not yet graded | No reviewed efficacy summary in this indication | |
| Zasocitinib | Phase 2 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-1451 | Phase 1(overall) | Undisclosed | IL-1α/IL-1β (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| SAR447971 | Phase 1(overall) | Small molecule | IRAK4 | not yet graded | No reviewed efficacy summary in this indication | |
| Tipasertideg | Discontinued | Small molecule | IRAK4 | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(12 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Bimzelx (bimekizumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (4)
2028 (5)
April 2028 (1)
What to watch
May 2028 (1)
What to watch
June 2028 (1)
What to watch
July 2028 (1)
August 2028 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent